| Literature DB >> 30382443 |
Adi Aran1, Hanoch Cassuto2, Asael Lubotzky3, Nadia Wattad3, Esther Hazan3.
Abstract
Anecdotal evidence of successful cannabis treatment in autism spectrum disorder (ASD) are accumulating but clinical studies are lacking. This retrospective study assessed tolerability and efficacy of cannabidiol-rich cannabis, in 60 children with ASD and severe behavioral problems (age = 11.8 ± 3.5, range 5.0-17.5; 77% low functioning; 83% boys). Efficacy was assessed using the Caregiver Global Impression of Change scale. Adverse events included sleep disturbances (14%) irritability (9%) and loss of appetite (9%). One girl who used higher tetrahydrocannabinol had a transient serious psychotic event which required treatment with an antipsychotic. Following the cannabis treatment, behavioral outbreaks were much improved or very much improved in 61% of patients. This preliminary study supports feasibility of CBD-based cannabis trials in children with ASD.Entities:
Keywords: Autism spectrum disorder; Cannabidiol; Disruptive behavior; Medical cannabis; Medical marijuana
Mesh:
Substances:
Year: 2019 PMID: 30382443 DOI: 10.1007/s10803-018-3808-2
Source DB: PubMed Journal: J Autism Dev Disord ISSN: 0162-3257